TRICE panel with CD138 IHC:
Introduction:
The TRICE Panel with CD138 IHC is a specialized diagnostic approach developed to provide a deeper evaluation of the endometrial lining in women experiencing persistent reproductive and gynecological challenges. The endometrium plays a vital role in embryo implantation, pregnancy maintenance, and overall uterine health, and even subtle inflammatory or immune-related abnormalities within this tissue can significantly affect fertility outcomes. Many women facing unexplained infertility, recurrent implantation failure during IVF treatment, repeated miscarriages, or chronic uterine symptoms may have underlying endometrial inflammation that is not easily identified through routine investigations alone. The TRICE Panel combines detailed histopathological examination with CD138 immunohistochemistry staining to improve the detection of plasma cells associated with Chronic Endometritis and other inflammatory changes affecting the uterine lining.
CD138 staining enhances the visibility of plasma cells under microscopic evaluation, allowing pathologists to identify hidden chronic inflammation with greater precision. This advanced analysis helps fertility specialists and gynecologists better understand the condition of the endometrium and determine whether immune-related abnormalities may be interfering with successful implantation or pregnancy progression. By providing more accurate and detailed diagnostic information, the TRICE Panel with CD138 IHC supports personalized treatment planning, targeted medical management, and improved reproductive care for women experiencing ongoing fertility-related concerns and unexplained uterine abnormalities.
What is the TRICE Panel with CD138 IHC?
The TRICE Panel with CD138 IHC is a specialized diagnostic evaluation used to assess chronic inflammatory and immune-related conditions affecting the endometrium. This advanced panel combines histopathological examination with immunohistochemistry staining using the CD138 marker to identify plasma cells associated with Chronic Endometritis. The test is particularly valuable for women facing infertility, recurrent implantation failure, recurrent pregnancy loss, unexplained uterine inflammation, and repeated unsuccessful fertility treatments. By providing detailed tissue analysis and immune cell evaluation, the TRICE Panel with CD138 IHC helps physicians understand underlying endometrial abnormalities that may interfere with implantation and reproductive success.
What is the cost of the TRICE Panel with CD138 IHC?
The cost of the TRICE Panel with CD138 IHC is ₹9,500. This pricing includes specialized histopathological evaluation, CD138 immunohistochemistry staining, microscopic tissue analysis, and expert pathological interpretation for detailed endometrial assessment.
Why is CD138 immunohistochemistry included in the TRICE Panel?
CD138 immunohistochemistry is included because plasma cells are considered an important indicator of chronic inflammation within the endometrium. Routine microscopic examination may not always identify these plasma cells accurately, especially when they are present in small numbers. CD138 staining highlights plasma cells more clearly, allowing pathologists to diagnose Chronic Endometritis with improved accuracy. Including CD138 IHC within the TRICE Panel enhances the ability to detect hidden inflammatory conditions that may affect fertility and uterine health.
What does the TRICE Panel evaluate?
The TRICE Panel evaluates the condition of the endometrial lining through detailed tissue examination and immune marker analysis. It helps identify chronic inflammation, immune-related abnormalities, plasma cell infiltration, and structural changes within the uterine lining. The panel provides valuable information regarding the health of the endometrium and its ability to support implantation and pregnancy. By analyzing both tissue architecture and immune activity, the test offers a more comprehensive assessment than routine histopathology alone.
Who should consider undergoing the TRICE Panel with CD138 IHC?
Women experiencing infertility, recurrent IVF failure, recurrent miscarriages, abnormal uterine bleeding, or unexplained reproductive challenges may benefit from this test. Doctors may also recommend the panel for patients with suspected Chronic Endometritis or abnormal endometrial findings during fertility evaluation. Women undergoing repeated fertility treatments without successful implantation often require deeper investigation of the uterine environment, making this advanced panel especially useful.
How is the sample collected for this test?
The tissue sample is generally collected through an endometrial biopsy or hysteroscopy-guided sampling procedure. A small sample from the uterine lining is obtained and sent to the laboratory for histopathological examination and immunohistochemistry staining. The procedure is usually completed within a short period and is often performed on an outpatient basis. Proper sample collection is essential for obtaining accurate and meaningful diagnostic information.
Can this test help identify Chronic Endometritis?
Yes, the TRICE Panel with CD138 IHC is highly useful for identifying Chronic Endometritis. The inclusion of CD138 staining helps detect plasma cells that indicate persistent inflammation within the endometrial lining. Chronic Endometritis can often remain undiagnosed during routine testing because symptoms may be subtle or absent. This advanced panel improves the accuracy of diagnosis and helps physicians identify hidden inflammatory conditions affecting reproductive health.
Why is Chronic Endometritis important in fertility evaluation?
Chronic Endometritis can negatively affect implantation, embryo development, and pregnancy continuation. Persistent inflammation within the uterus may alter the endometrial environment and reduce its ability to support successful pregnancy. Many women with repeated IVF failure or recurrent miscarriage are later found to have chronic endometrial inflammation. Identifying and treating this condition can improve fertility outcomes and increase the chances of successful implantation and pregnancy.
Is this test useful for IVF patients?
Yes, IVF patients frequently undergo the TRICE Panel with CD138 IHC when repeated embryo transfers fail despite good embryo quality. Hidden endometrial inflammation can interfere with implantation even when other fertility factors appear normal. This panel helps fertility specialists identify uterine abnormalities that may be reducing the chances of treatment success. Accurate diagnosis allows doctors to provide targeted therapy before future IVF cycles.
How accurate is the TRICE Panel with CD138 IHC?
The test is considered highly informative because it combines microscopic tissue analysis with targeted immunohistochemistry staining. CD138 improves the visibility of plasma cells and enhances diagnostic sensitivity for chronic inflammation. The combination of histopathology and immune marker evaluation provides more reliable information regarding endometrial health and inflammatory activity. Expert pathological interpretation further improves the accuracy of the final diagnosis.
Can this test help women with recurrent miscarriages?
Yes, women experiencing repeated pregnancy loss may benefit from this panel because chronic inflammation within the endometrium can interfere with embryo implantation and pregnancy maintenance. Identifying underlying inflammatory abnormalities allows doctors to begin appropriate treatment aimed at improving uterine receptivity and reducing the risk of future miscarriage. Detailed endometrial evaluation is often an important part of recurrent pregnancy loss investigations.
Is the biopsy procedure painful?
Some women may experience mild cramping, pressure, or temporary discomfort during endometrial biopsy procedures. The level of discomfort varies depending on individual sensitivity and the sampling method used. Most patients tolerate the procedure well, and any discomfort generally resolves within a short time. Mild spotting or cramping may continue briefly after sample collection.
Can this panel detect hidden inflammation?
Yes, one of the major advantages of this panel is its ability to detect hidden or subtle inflammatory changes that may not be obvious during routine examination. CD138 immunohistochemistry improves the identification of plasma cells within the endometrial tissue, helping pathologists recognize chronic inflammatory conditions more accurately. Detecting hidden inflammation is important because untreated abnormalities may continue affecting fertility outcomes.
Why are plasma cells important in endometrial evaluation?
Plasma cells are immune cells that indicate chronic inflammation when found within the endometrial tissue. Their presence is considered one of the most important microscopic findings associated with Chronic Endometritis. However, plasma cells may be difficult to identify using standard staining methods alone. CD138 immunohistochemistry specifically highlights these cells, making diagnosis more precise and reliable.
Can this test improve treatment planning?
Yes, the TRICE Panel with CD138 IHC provides detailed diagnostic information that helps physicians create individualized treatment strategies. By identifying chronic inflammation and immune-related abnormalities within the endometrium, doctors can recommend targeted therapies before fertility treatment or pregnancy attempts. Personalized treatment based on accurate diagnosis may improve implantation success and reproductive outcomes.
Are the test results confidential?
Yes, patient confidentiality is maintained throughout the testing and reporting process. Laboratories follow strict privacy protocols to protect medical records and diagnostic findings. Reports are generally shared only with authorized healthcare professionals or individuals approved by the patient. Maintaining privacy is an essential part of professional healthcare practice.
Why is early diagnosis of endometrial inflammation important?
Early diagnosis is important because persistent inflammation within the uterus can continue affecting implantation, fertility, and pregnancy outcomes over time. Delayed diagnosis may lead to repeated IVF failure, recurrent miscarriages, or ongoing gynecological symptoms. Timely identification through advanced testing allows doctors to begin treatment earlier and improve reproductive health outcomes more effectively.
Why should patients choose the TRICE Panel with CD138 IHC?
The TRICE Panel with CD138 IHC provides a detailed and advanced evaluation of endometrial health by combining histopathology with targeted immunohistochemistry analysis. This comprehensive approach improves the detection of chronic inflammation and immune-related abnormalities that may interfere with fertility and successful pregnancy. Accurate diagnosis helps physicians guide personalized treatment, improve uterine receptivity, and support better reproductive outcomes. With advanced laboratory methods and expert interpretation, the TRICE Panel with CD138 IHC serves as a valuable diagnostic tool in modern fertility and gynecological care.
How long does it take to receive the results?
The turnaround time for the TRICE Panel with CD138 IHC it takes 4 to 6 days may vary depending on laboratory processing and immunohistochemistry analysis requirements. Since the tissue sample undergoes detailed staining and microscopic interpretation, several days may be required before the final report is issued. Patients should review the results with their healthcare provider for complete understanding and treatment guidance.
Conclusion:
The TRICE Panel with CD138 IHC serves as an important diagnostic tool for evaluating chronic inflammatory and immune-related conditions affecting the endometrial lining. Through the combination of histopathological examination and advanced immunohistochemistry staining, this test offers greater diagnostic sensitivity for identifying plasma cells and subtle inflammatory changes that may remain undetected during routine microscopic evaluation. Accurate recognition of Chronic Endometritis and related endometrial abnormalities is extremely important because persistent inflammation can interfere with embryo implantation, fertility treatment success, and healthy pregnancy development. Early diagnosis allows healthcare providers to recommend timely and targeted treatment strategies aimed at improving uterine receptivity and reproductive outcomes.
